FDA Approval Shortens Manufacturing Process for CAR T-Cell Therapy Yescarta

The FDA has approved a manufacturing process change for Yescarta (axicabtagene ciloleucel) allowing for a shorter manufacturing time.

Related Keywords

Cindy Perettie , Drug Administration , Executive Vice President ,